• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025

by admin | Apr 14, 2025 | Investor Presentations

Result of 2024 Annual General Meeting

by admin | Oct 25, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Notice of Annual General Meeting October 2024

by admin | Oct 25, 2024 | Annual General Meeting

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces strengthening of leadership team as it closes on value-generating inflection points

by admin | Oct 22, 2024 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Notice of AGM

by admin | Oct 1, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference
  • H.C. Wainwright 28th Annual Global Investment Conference
  • Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy